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Abstract
OBJECTIVE: To evaluate the effect of Huadanansh-
en mistura in clinical treatment of Chinese patients
with insomnia.
METHODS: In this randomized, double-blind, pla-
cebo-controlled, multi-center study, 244 patients
with insomnia were randomly assigned to a place-
bo group, a low-dose (10 mL/day), or a high-dose
(20 mL/day) mistura group. Efficacy was assessed
by using the sleep dysfunction rating scale (SDRS)
and Clinical Global Impression-Improvement (CGI-I)
scores. Safety and tolerability assessments included
emergent adverse events, laboratory tests, and
electrocardiograms.
RESULTS: Total SDRS scores decreased in all three
groups, and there were significant differences be-
tween the placebo group and the low- and
high-dose mistura groups (P=0.000). CGI-I ratings
in the low- and high-dose mistura groups were sig-
nificantly better than that of the placebo group (P=
0.000). Incidences of rebound insomnia were simi-
lar in all three groups (placebo group: 6.94% ,
low-dose mistura group: 12.99% , and high-dose
mistura group: 10.96% ; P=0.475). The efficacy of
Huadananshen mistura in the low- or high-dose
group was significantly better than that of the pla-
cebo group (P=0.000), but with no significant differ-
ence found between the low- and high-dose mistu-
ra groups (P=0.887). The rates of adverse events
were similar in the three groups (placebo 2.44% ,
low-dose mistura 0% , and high-dose mistura 5% ;
P=0.088).
CONCLUSION: Huadananshen mistura is an effec-
tive and generally well-tolerated hypnotic medi-
cine for the treatment of Chinese patients with in-
somnia.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Insomnia is the most common sleeping problem in the
general population, with a prevalence of about
13%-45% depending on the criteria used.1-3 With so-
cial and economic development, more people suffer
from insomnia, especially women and the elderly.
Many western hypnotics have been developed in recent
years, such as benzodiazepine derivatives, non-benzodi-
azepine hypnotics, and z-drugs like zolpidem, zopi-
clone, eszopiclone and zaleplon.4,5 Each drug acts on
423
JTCM |www. journaltcm. com
Li HF et al. / Clinical Study
August 15, 2013 |Volume 33 | Issue 4 |
neurotransmitters or receptors to produce sedative and
hypnotic effects. However, the medications have short
durations of action, and some have a risk of tolerance
or abuse.6 They may also cause impairments in memo-
ry and cognitive function, especially benzodiazepine de-
rivatives.7
Huadananshen mistura (Mind-tranquilizing Mixture
of Huadan Brand, mistura) is a modern Traditional
Chinese Medicine. The main ingredients are the twigs
and leaves of the peanut and Danshen (Radix Salviae
Miltiorrhizae). Huadananshen mistura was developed
by the Shanghai Science and Technology Commission
from December 2000 to December 2002. The peanut
plant opens its leaves in the daytime and closes them
in the evening, just like normal people work in the
daytime and sleep at night. This indicates that the
peanut leaf possibly contains sleep-promoting sub-
stances.8-12 Toxicological study9 found that the LD 50
was 141.75 g/kg, or 283 times the clinical dosage.
Long-term toxicity tests9 showed that there were no sig-
nificant changes in blood indexes and biochemical pa-
rameters of rats taking Huadananshen mistura for 3
months. Only the clotting time was prolonged in male
rats in the medication group. Pre-clinical trials10-12 dem-
onstrated that Huadananshen mistura can improve
sleep, and adverse reactions are similar to the placebo.
Huadananshen mistura was approved as a hypnotic
medicine by the State Food and Drug Administration
(SFDA) of China in September 2004 (File No.
2004L03248, Chinese Traditional Medicine Category
Six). We conducted this randomized controlled trial
(RCT) to evaluate the efficacy and safety of Huadanan-
shen mistura in the clinical treatment of insomnia, and
observe rebound insomnia after medication end.
METHODS
This randomized double-blind, placebo-controlled
multi-center clinical trial was designed to evaluate the
efficacy and safety of low- or high-dose Huadananshen
mistura in the clinical treatment of insomnia.
Subjects
Patients that were aged 18 to 65 years, had been admit-
ted to hospital, and met the DSM-IV criteria for in-
somnia were recruited into the study. The exclusion cri-
teria were: (a) alcoholics, drug addicts, or pregnant or
lactating women; (b) insomnia caused by drugs, alco-
hol, or physical and mental illness; (c) patients under-
going regular antipsychotic or antidepressant treatment
4 weeks before the enrollment; (d) patients with signifi-
cant heart, liver, kidney or other major diseases; (e) lab-
oratory tests and electrocardiogram (ECG) indicating
significant abnormalities, with AST or ALT more than
1.5 times the normal upper limit; (f ) allergies to
Huadananshen mistura; (g) Hamilton anxiety rating
scale (HAM-A) score ≥14, or Hamilton depression rat-
ing scale (HDRS) score ≥18; or (h) undergoing other
clinical trials within 30 days of the study.
Study design
This trial was conducted in three hospitals (Shanghai
Mental Health Center, Shanghai Huashan Hospital,
and Shanghai Yueyang Hospital) from March 2005 to
December 2006. According to the sample size, the ta-
ble of random numbers was produced by statistical soft-
ware SAS 6.12 (SAS Institute Inc., Cary, NC, USA).
All patients were randomly assigned to the low-dose
mistura, high-dose mistura, or placebo group. Patients
took 10 or 20 mL of Huadananshen mistura, or the
placebo, orally every night for 2 weeks. There was a
1-week follow-up observation for rebound insomnia.
The study protocol was reviewed and approved by the
Institutional Review Board of Shanghai Mental Health
Center, and the study was approved by the Ethic Com-
mittee of Shanghai Mental Health Center. Written in-
formed consent was signed by all subjects before any
study-related activities.
Medication and administration
Patients took Huadananshen mistura oral liquid (10 or
20 mL every night) or placebo for 2 weeks. They were
asked to suspend all other hypnotics during the trial.
Any psychiatric medications, including antipsychotics,
antidepressants, anxiolytics, were forbidden.
The Huadananshen mistura oral liquid and the place-
bo were similar in appearance and taste and were pro-
duced by Shanghai Baolong Pharmaceutical Corpora-
tion (Shanghai, China) (Batch No. 050401 and
050101). Personnel involved in the manufacturing and
packaging of the medications were not allowed to con-
tact the subjects or the research personnel.
For all subjects, a physical examination, an ECG, and
blood tests including serum creatinine, aspartate ami-
notransferase, alanine aminotransferase, and urea ni-
trogen were performed. Laboratory tests were done at
the beginning and end of the 2-week trial. Investiga-
tors documented and recorded adverse events and
concomitant medications. Finally, the medication
containers and remaining drugs were withdrawn
from all subjects.
Efficacy evaluation
Efficacy evaluations were made according to the base-
line at the end of 1- and 2-weeks, based primarily on
changes in the total sleep dysfunction rating scale
(SDRS) scores. Secondary efficacy measures included
the reduction rate of SDRS scores and changes Clinical
Global Impression-Improvement (CGI-I) scores. Clini-
cal recovery was defined as a reduction rate ≥80%. If
the reduction rate was between 50% and 79% , then
the clinical efficacy was markedly effective. If the reduc-
tion rate was between 30% and 49%, then it was effec-
tive. Recovery was invalid if the reduction rate was less
than 30%. The effective rate was the sum of the clini-
cal recovery and marked effect.
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Safety evaluation
Spontaneous reports about emergent adverse events
(AEs) were collected daily. AEs were defined as untow-
ard medical events occurring during the clinical trial,
regardless of whether or not there was a close relation
with Huadananshen mistura. AEs included: (a) all
the drug's suspected adverse reactions; (b) the allergic
or toxic reaction due to overdose or abuse; (c) wors-
ening of unrelated diseases; (d) injury or accident; (e)
abnormalities found by physical examination or labo-
ratory tests, needing further investigation or clinical
treatment. When the investigator recorded the CRF
of adverse events, they used three grades (mild, mod-
erate, and severe) to describe the condition of ad-
verse events.
Statistical analysis
The study was analyzed with the principle of intention
to treat (ITT). The primary analysis of efficacy end-
points was performed for the full analysis set (FAS)
population, including all patients who were randomly
assigned to treatment, who received at least one dose of
the study medication, and who had at least a baseline
and one post-baseline assessment. The endpoint was
defined as the last observation carried forward . Second-
ary analyses were also carried out for the per-protocol
set (PPS), which included all FAS patients who had
good compliance, did take prohibited medication, and
had a clinical observation duration of more than 2
weeks. Safety evaluation proceeded according to the
safety set (SS), which included all randomized sub-
jects who received at least one dose of the study med-
ication.
T-tests were used to compare the quantitative parame-
ters of normal distributions and the Wilcoxon
rank-sum test was used to compare the quantitative pa-
rameters of non-normal distributions by SPSS 15.0
(SPSS Inc., Chicago, IL, USA). Cochran Man-
tel-Haenszel Chi-squared test was used to analyze the
differences in ordinal segment parameters between
groups. An analysis of covariance was used to analyze
the difference in qualitative parameters between
groups, which included the baseline score and gender
as the covariates, and the treatment center as a random
effect. All the statistical tests were two-tailed, and the
significance was set to P<0.05.
RESULTS
The 252 patients recruited to participate in this trial
were from three hospitals in Shanghai, and were ran-
domly divided into three groups. Twenty-five patients
dropped out because of adverse events, invalid effects,
lost follow-up, or revocation of informed consent.
Eight patients (two in the placebo group, two in
low-dose mistura group and four in high-dose mistura
group) that could not enter into any analysis sets were
removed. 244 patients were included in the FAS, 229
in the PPS, and 244 in the SS. The baseline demo-
graphic characteristics are shown in Table 1. There
were no significant differences between the three
groups at the baseline in terms of demographic vari-
ables (P>0.05).
Efficacy of Huadananshen mistura for treating
insomnia
All patients showed improvements in quality of sleep
and total SDRS scores gradually decreased in the three
groups during the 2-week clinical trial (Figure 1). Com-
paring the total scores of SDRS before and after treat-
ment, the score at the baseline was 26±6 in the placebo
group, 27±6 in the low-dose mistura group, and 26±6
in the high-dose mistura group. After a 2-week treat-
ment, the score was 18±9 in the placebo group, 13±6
in the low-dose mistura group and 13 ± 7 in the
high-dose mistura group. There were significant differ-
ences at each measured time point during the treat-
ment between the placebo group and the low- and
high-dose mistura groups (P=0.000). However, there
were no significant differences between the low-dose
mistura group and the high-dose mistura group. The
SDRS scores in the 2-week and 3-week treatment
showed no significant differences among the three
groups (P=0.319).
According to the CGI-I scores, there were no statistical-
ly significant differences among the three groups at the
baseline (placebo group: 4.5 ± 1.0, low-dose mistura
group: 4.6±1.0, and high-dose mistura group: 4.4±0.9;
P=0.635). Throughout the study, the mean scores grad-
ually decreased in the three groups, and the changes
were statistically significant at week 1 (placebo group:
3.7 ± 1.1, low-dose mistura group: 3.4 ± 1.1, and
high-dose mistura group: 3.2 ± 1.0; P=0.024), and at
the end of the 2-week treatment (placebo group: 3.6±
1.1, low-dose mistura group: 2.8 ± 1.1, and high-dose
mistura group: 2.6±1.4; P=0.000). The improvements
in CGI-I scores were statistically significant at week 1
(P=0.032) and week 2 (P=0.000) in all three groups.
The improvement of CGI-I in the low- or high-dose
mistura group was significantly better than that of the
placebo group (P=0.000). However, there were no sig-
nificant differences between the low- and high-dose
mistura groups (P=0.920 at week 1 and P=0.839 at
week 2).
We also observed the incidence of rebound insomnia
after medication cessation at the end of the 2-week
treatment. The occurrence rates of rebound insomnia
were 6.94%, 12.99%, and 10.96%, respectively, in the
placebo, low-dose mistura, and high-dose mistura
groups. There were no significant differences among
the three groups (P=0.475). However, the duration of
rebound insomnia was similarly about 2-3 days in the
three groups (P=0.376).
Adverse events
In the safety analysis of 82 patients in the placebo
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group, 82 patients in the low-dose mistura group, and
80 patients in the high-dose mistura group, the inci-
dence of the possible study drug-related AEs generally
reflected the known safety profiles of Huadananshen
mistura. The overall incidence of AEs was 2.44% in
the placebo group, 5% in the high-dose mistura group,
while no AEs were found in the low-dose mistura
group. There were no significant differences in the inci-
dence of AEs among the three groups (P=0.088). Most
AEs were nausea, vomiting, and gastrointestinal reac-
tions. One of the AEs in the placebo group was moder-
ate bronchiectasis complicated by hemoptysis, but the
patient had a previous history, not related to Huadan-
anshen mistura.
DISCUSSION
This randomized, double-blind, placebo-controlled
clinical study followed Good clinical practice (GCP)
management specifications for China. The study was
performed in three hospitals to evaluate the efficacy
and safety of Huadananshen mistura in patients with
insomnia. The findings from the primary endpoints
demonstrated that 10 and 20 mL/day Huadananshen
mistura were more effective than the placebo for treat-
ing insomnia.
The results from the present study are supported by
the other studies,13,14 demonstrating that Huadanansh-
en mistura has efficacy in the treatment of insomnia.
For example, Wang et al 13 observed the clinical efficacy
Variable
Age (year)
Gender
Marriage status
Family status
Insomnia status
Causing factor
Previous
treatment
Duration of the disease (month)
Total duration of the disease (month)
Combined drug usage [n (%)]
Total score of HAMA
Total score of HDRS
Male (%)
Female (%)
Married [n (%)]
Divorced or separated [n (%)]
Unmarried [n (%)]
Spouse [n (%)]
Parents [n (%)]
Solitary [n (%)]
Others [n (%)]
First episode [n (%)]
Recurrence [n (%)]
Chronic [n (%)]
No factors [n (%)]
Physical illness [n (%)]
Psycho-social pressure [n (%)]
Physical illness and pressure [n (%)]
Unclear factors [n (%)]
No any treatment [n (%)]
Have been treated [n (%)]
Placebo (n=82)
47±11
26 (31.71)
56 (68.29)
75 (91.46)
1 (1.22)
6 (7.32)
74 (90.24)
5 (6.10)
1 (1.22)
2 (2.44)
32 (39.02)
23 (28.05)
27 (32.93)
36 (43.90)
1 (1.22)
13 (15.85)
0 (0.00)
32 (39.02)
54 (65.85)
28 (34.15)
8±15
36±70
11 (13.41)
5±3
6±2
Low-dose (n=82)
47±12
25 (30.49)
57 (69.51)
74 (90.24)
2 (2.44)
6 (7.32)
74 (90.24)
2 (2.44)
1 (1.22)
5 (6.10)
19 (23.17)
27 (32.93)
36 (43.90)
30 (36.59)
2 (2.44)
16 (19.51)
1 (1.22)
33 (40.24)
55 (67.07)
27 (32.93)
10±14
42±69
8 (9.76)
5±3
6±2
High-dose (n=80)
48±12
19 (23.75)
61 (76.25)
74 (92.50)
0 (0.00)
6 (7.50)
72 (90.00)
3 (3.75)
2 (2.50)
3 (3.75)
22 (27.50)
32 (40.00)
26 (32.50)
32 (40.00)
2 (2.50)
16 (20.00)
0 (0.00)
30 (37.50)
55 (68.75)
25 (31.25)
8±11
37±65
8 (10.00)
5±3
6±3
P
0.652
0.485
0.873
0.819
0.133
0.961
0.927
0.472
0.446
0.763
0.613
0.935
Notes: placebo group: similar appearance liquid; low-dose group: 10 mL/day mistura; high-dose group: 20 mL/day mistura. HAMA: ham-
ilton anxiety rating scale; HDRS: hamilton depression rating scale.
Table 1 Baseline demographic characteristics of insomnia patients
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of peanut twigs and leaves in a controlled study of 458
patients with insomnia, and found that the total effec-
tive rate was 96% in the treatment group of 100 cases.
Another randomized, double-blind, and placebo-con-
trolled clinical trial had a total effective rate of 73.6%
in a peanut preparation group, but 43.2% in the place-
bo group.14
The clinical efficacies of benzodiazepine derivatives
and non-benzodiazepine hypnotics have been recog-
nized, but their use may induce many side effects, such
as rebound insomnia and residual sedation.15 Rebound
insomnia often aggravates clinical symptoms, especially
after withdrawal of a short-term treatment. In the pres-
ent study, the occurrence rates of rebound insomnia
were 6.94% , 12.99% , and 10.96% in the placebo,
low-dose, and high-dose mistura groups, respectively,
within 1 week following an abrupt discontinuation of
the medication, with no significant differences among
the three groups. No unexpected adverse events or seri-
ous adverse events appeared in the low- or high-dose
mistura groups. To sum up, Huadananshen mistura is
effective for treating insomnia and the dose of mistura
is well tolerated and safe.
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Figure 1 Changes in the total SDRS scores at multiple time points (FAS and PPS)
Placebo group: similar appearance liquid; Low-dose group: 10 mL/day mistura; High-dose group: 20 mL/day mistura. SDRS: Sleep
dysfunction rating scale; FAS: full analysis set; PPS: per-protocol set. At the end of 2 weeks' treatment, the clinical recovery rate
and effective rate were 6.10% and 26.83% in the placebo group, respectively. In the low-dose mistura group, the rates were 8.54%
and 68.29%, respectively. In the high-dose mistura group, the rates were 5.00% and 70.00%, respectively. The efficacy of Huadan-
anshen mistura in the low- or high-dose was significantly better than that of placebo (P=0.000), but there was no significant differ-
ence between the low-dose and high-dose mistura groups (P=0.887).
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